Evidence map›Paper›PMID 40416540›Full record

ArticleIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine2025

Evaluating the Role of Serum Beta-D-glucan Testing in Safely Reducing Antifungal Therapy in Critically Ill Patients: A Retrospective Study.

Ripenmeet Salhotra, Debasish Biswal, Narayanan Sarat, Aayush Chawla, Sandeep Mangla, Pranjal Gupta, Rajeshwari Subramaniam

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Optimizing the Treatment of Critically Ill Patients Utilizing Beta-D-glucan: The Time is Now.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ripenmeet SalhotraDepartment of Anesthesia and Critical Care, Amrita Institute of Medical Sciences and Research Centre, Faridabad, Haryana, India.ORCID https://orcid.org/0000-0001-8987-6102
Debasish BiswalDepartment of Microbiology, Amrita institute of Medical Sciences and Research Centre, Faridabad, Haryana, India.ORCID https://orcid.org/0000-0003-3119-359X
Narayanan SaratDepartment of Critical Care, Amrita Institute of Medical Sciences and Research Centre, Faridabad, Haryana, India.ORCID https://orcid.org/0009-0008-5396-4889
Aayush ChawlaDepartment of Anaesthesiology and Critical Care, Amrita Institute of Medical Sciences and Research Centre, Faridabad, Haryana, India.ORCID https://orcid.org/0000-0002-9545-5299
Sandeep ManglaDepartment of Anaesthesiology and Critical Care, Amrita Institute of Medical Sciences and Research Centre, Faridabad, Haryana, India.ORCID https://orcid.org/0000-0002-0409-8717
Pranjal GuptaDepartment of Anaesthesiology and Critical Care, Amrita Institute of Medical Sciences and Research Centre, Faridabad, Haryana, India.ORCID https://orcid.org/0009-0009-9779-6431
Rajeshwari SubramaniamDepartment of Obstetrics and Pediatric Anaesthesia and Critical Care Medicine, Amrita Institute of Medical Sciences and Research Centre, Faridabad, Haryana, India.ORCID https://orcid.org/0000-0002-3830-5278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: The role of (1→3)-β-D-glucan (BDG) testing in guiding antifungal therapy (AFT) in critically ill patients remains unclear. While BDG has a high negative predictive value (NPV), is it safe to withhold AFT in critically ill BDG-negative patients has not been well studied. Patients and methods: This retrospective cohort study analyzed BDG-negative intensive care unit (ICU) patients (<60 pg/mL) at a tertiary care hospital from March 2024 to January 2025. The ICU survival was compared between those who received AFT and those who did not. Propensity score matching (PSM) adjusted for illness severity, and logistic regression identified independent predictors of survival. Results: Among 100 BDG-tested patients, 53 (53%) were BDG-negative. Of these, 22 (41.5%) received AFT, while 31 (58.5%) did not. Unadjusted ICU survival was lower in the AFT group (45.5%) vs no AFT (80.6%) ( Conclusions: Withholding AFT in BDG-negative critically ill patients did not impact ICU survival, supporting BDG's role in antifungal stewardship. However, its limitations in detecting Candida auris warrant further prospective studies. How to cite this article: Salhotra R, Biswal D, Sarat N, Chawla A, Mangla S, Gupta P,

Indexed as

Antifungal stewardshipAntifungal therapyBeta-D-glucanChart reviewICU survivalInvasive candidiasis retrospective cohort

Identifiers

PMID40416540
PMCPMC12101973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.